Joseph Moscato
Director Ejecutivo en GENEREX BIOTECHNOLOGY CORPORATION .
Cargos activos de Joseph Moscato
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
GENEREX BIOTECHNOLOGY CORPORATION | Director Ejecutivo | 21/11/2017 | - |
Presidente | 21/11/2017 | - | |
Presidente | 21/11/2017 | - | |
NUGENEREX IMMUNO-ONCOLOGY, INC. | Director Ejecutivo | 01/01/2017 | - |
Presidente | 01/01/2017 | - |
Historial de carrera de Joseph Moscato
Antiguos cargos conocidos de Joseph Moscato.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Seahawk Capital Corp.
Seahawk Capital Corp. Food: Specialty/CandyConsumer Non-Durables Seahawk Capital Corp. provides food processing and distribution services. The company is based in Cherry Hill, NJ. | Corporate Officer/Principal | 11/05/2011 | 15/12/2011 |
Estadísticas
Internacional
Estados Unidos | 4 |
Operativa
Chairman | 2 |
Chief Executive Officer | 2 |
Corporate Officer/Principal | 1 |
Sectorial
Health Technology | 3 |
Consumer Non-Durables | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Seahawk Capital Corp.
Seahawk Capital Corp. Food: Specialty/CandyConsumer Non-Durables Seahawk Capital Corp. provides food processing and distribution services. The company is based in Cherry Hill, NJ. | Consumer Non-Durables |
Generex Biotechnology Corp.
Generex Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Generex Biotechnology Corp. is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. It builds new kind of healthcare company, which provides support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. The company was founded by Rose C. Perri on September 4, 1997 and is headquartered in Miramar, FL. | Health Technology |
NuGenerex Immuno-Oncology, Inc.
NuGenerex Immuno-Oncology, Inc. BiotechnologyHealth Technology NuGenerex Immuno-Oncology, Inc. is an oncology company focuses on the modulation of the immune system to treat cancer. It develops immunotherapeutic products and vaccines based on proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) class II associated invariant chain that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The company was founded on October 8, 1993 and is headquartered in Miramar, FL. | Health Technology |
- Bolsa de valores
- Insiders
- Joseph Moscato
- Experiencia